Bullish & Foolish
Full KALA fundamentals All 466 on the Survival Watch

KALAKALA BIO, Inc.

Is KALA BIO struggling financially?

Yes, by its own account. KALA BIO told the SEC on 15 Apr 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Apr 2026

0/100

Critical

Cries for help

  • Trial setback

    In February 2023, we dosed our first patient in the United States in our CHASE trial (the “CHASE trial”). By September 2025, the CHASE trial did not meet its primary endpoints, and we determined to discontinue our development of KPI-012 and the MSC-S platform.

    Form 10-Q, filed 15 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$15.9M
Source filing
10-K 15 Apr 2026
Balance sheet
31 Mar 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash and short-term investments

$8.8M

What KALA BIO told the SEC

…more fully in the “Risk Factors” section of this Annual Report on Form 10-K. Our principal risks include the following: The Company’s auditor has noted substantial doubt about our ability to continue as a going concern. We have incurred significant losses from operations and negative cash flows from operations since our inception. We expect to incur additional losses and may never achieve or…

KALA BIO, Inc., Form 10-K, filed 15 Apr 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 87.1% share-count increase The company issued stock. Each share now owns 46.6% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt